-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
During the "13th Five-Year Plan" period, the market structure of China's pharmaceutical industry has undergone significant changes
.
What are the underlying reasons for these changes? Which aspects of the industry have an important impact?
.
What are the underlying reasons for these changes? Which aspects of the industry have an important impact?
Recently, Hengrui's share price was cut in half and Dongyang Sunshine announced that it intends to divest its pharmaceutical business and other events that have attracted industry attention
.
Ripples frequently occur in China's pharmaceutical industry
.
.
Ripples frequently occur in China's pharmaceutical industry
.
Everything has historical reasons, either macroscopically or microscopically
.
Looking back, since the "13th Five-Year Plan", China's pharmaceutical industry has carried out drastic reforms, the industry's "metabolism" has accelerated, and the market structure has been restructured
.
Catalyzed by the impact of the new crown pneumonia epidemic, China's pharmaceutical industry has accelerated its restructuring amid opportunities and challenges
.
.
Looking back, since the "13th Five-Year Plan", China's pharmaceutical industry has carried out drastic reforms, the industry's "metabolism" has accelerated, and the market structure has been restructured
.
Catalyzed by the impact of the new crown pneumonia epidemic, China's pharmaceutical industry has accelerated its restructuring amid opportunities and challenges
.
The market is the ultimate manifestation of the development characteristics of all levels of the industry
.
From the perspective of the market, this article briefly presents and analyzes the turbulent history of China's pharmaceutical industry during the 13th Five-Year Plan period
.
.
From the perspective of the market, this article briefly presents and analyzes the turbulent history of China's pharmaceutical industry during the 13th Five-Year Plan period
.
Market differentiation: Biological medicines are gaining momentum, Chinese medicines remain stable, and chemical medicines are not in sight
After years of market expansion, the market size of China's pharmaceutical industry will exceed 1.
700 billion yuan in 2020
.
Among the three major areas, biological drugs are developing rapidly, and their scale proportions are increasing year by year, reaching 20.
84% in 2020; the proportion of traditional Chinese medicines is stable, remaining at about 25%; chemical medicines are in the transitional period, and the market share has dropped significantly, and its loss is This can be seen in the recent incidents of traditional large chemical pharmaceutical companies such as Hengrui and Dongyang Sunshine
.
The differentiated development of the three major pharmaceutical markets is closely related to the implementation of policies in each field and the entry of new products
.
700 billion yuan in 2020
.
Among the three major areas, biological drugs are developing rapidly, and their scale proportions are increasing year by year, reaching 20.
84% in 2020; the proportion of traditional Chinese medicines is stable, remaining at about 25%; chemical medicines are in the transitional period, and the market share has dropped significantly, and its loss is This can be seen in the recent incidents of traditional large chemical pharmaceutical companies such as Hengrui and Dongyang Sunshine
.
The differentiated development of the three major pharmaceutical markets is closely related to the implementation of policies in each field and the entry of new products
.
2016-2020 China's pharmaceutical industry market size and market segment proportions
Data source: Blue Book of China's Health Industry
Market differentiation is also reflected in the change of heavyweight varieties
.
From 2016 to 2020, among the Top 20 categories of drug sales in the Chinese hospital market, many products have either changed their rankings or entered or departed from the rankings
.
Chemical drugs such as atorvastatin, clopidogrel, and entecavir have gradually disappeared from the Top 20 list after undergoing centralized harvesting, while biological drugs such as bevacizumab and trastuzumab have been eye-catching
.
.
From 2016 to 2020, among the Top 20 categories of drug sales in the Chinese hospital market, many products have either changed their rankings or entered or departed from the rankings
.
Chemical drugs such as atorvastatin, clopidogrel, and entecavir have gradually disappeared from the Top 20 list after undergoing centralized harvesting, while biological drugs such as bevacizumab and trastuzumab have been eye-catching
.
Changes in the List of Top 20 Drug Sales in China's Hospital Market from 2016 to 2020
Data source: Pharmaceutical Comprehensive Database (PDB), China Pharmaceutical Industry Information Center
Increased concentration: industry structure changes under the empowerment of heavy new varieties
In recent years, the market concentration of China's pharmaceutical industry has increased rapidly
.
From 2016 to 2020, the market share of Top 20 corporate hospitals has steadily increased, reaching 26.
26% in 2016 and reaching 32.
82% in 2020
.
Top20 companies have occupied nearly one-third of the hospital market
.
.
From 2016 to 2020, the market share of Top 20 corporate hospitals has steadily increased, reaching 26.
26% in 2016 and reaching 32.
82% in 2020
.
Top20 companies have occupied nearly one-third of the hospital market
.
Changes in market share of top 20 companies in China's hospital market by drug sales from 2016 to 2020
Data source: Pharmaceutical Comprehensive Database (PDB), China Pharmaceutical Industry Information Center
Among the Top 20 companies, the number of foreign-funded companies has increased from 9 in 2016 to 11 in 2020, and the total market share of foreign-funded companies has increased from 51.
26% in 2016 to 61.
82% in 2020.
This is in line with the acceleration of foreign blockbuster innovative products to enter the domestic market.
Closely related
.
26% in 2016 to 61.
82% in 2020.
This is in line with the acceleration of foreign blockbuster innovative products to enter the domestic market.
Closely related
.
Changes in the share of Chinese domestic and foreign companies in the top 20 pharmaceutical sales in China's hospital market from 2016 to 2020
Data source: Pharmaceutical Comprehensive Database (PDB), China Pharmaceutical Industry Information Center
Under the influence of factors such as the acceleration of the review and approval of new drugs by the State Food and Drug Administration, acceptance of overseas clinical trial data, centralized procurement to promote patent cliffs, and more convenient access to medical insurance catalogs, foreign companies have accelerated the entry of new products into China
.
Taking imported chemical drugs as an example, from 2016 to 2020, the total number of clinical trial applications and marketing applications for imported chemical drugs accepted by CDE has increased year by year
.
In 2020, a total of 3 imported innovative drugs will be applied for listing in China.
Compared with 1 in 2018 and 2019, there is a significant breakthrough
.
The admission of new overseas varieties has greatly benefited the availability of medicines for Chinese patients
.
.
Taking imported chemical drugs as an example, from 2016 to 2020, the total number of clinical trial applications and marketing applications for imported chemical drugs accepted by CDE has increased year by year
.
In 2020, a total of 3 imported innovative drugs will be applied for listing in China.
Compared with 1 in 2018 and 2019, there is a significant breakthrough
.
The admission of new overseas varieties has greatly benefited the availability of medicines for Chinese patients
.
2016-2020 China imported chemical drug clinical trial application status (according to the acceptance number)
Data source: China New Drug Research and Development Monitoring Database (CPM), China Pharmaceutical Industry Information Center
2016-2020 China's import chemical drug listing application status (according to the acceptance number)
Data source: China New Drug Research and Development Monitoring Database (CPM), China Pharmaceutical Industry Information Center
Imported innovative drug listing application information
Data source: China New Drug Research and Development Monitoring Database (CPM), China Pharmaceutical Industry Information Center
Channel adjustment: multi-method incremental exploration
With the implementation of prescription outflow and centralized procurement policies, the stock of the hospital market has shrunk, and the out-of-hospital market has become a gold dig for pharmaceutical companies
.
After years of drug control fees and prescription assessments, public medical institutions are still the main drug sales market in China, but their market share is steadily decreasing.
In 2020, public medical institutions’ drug sales accounted for 58.
18% of the overall market, a decrease of 2.
2 units from 2019 Percentage points
.
The importance of retail pharmacies in the pharmaceutical market is increasing.
In 2020, China's retail pharmacies accounted for 26.
02% of drug sales, an increase of 1.
8 percentage points from 2019
.
Driven by hierarchical diagnosis and treatment and centralized procurement, channel sinking has become a marketing strategy for pharmaceutical companies, and the proportion of drug sales in primary medical institutions is on the rise
.
.
After years of drug control fees and prescription assessments, public medical institutions are still the main drug sales market in China, but their market share is steadily decreasing.
In 2020, public medical institutions’ drug sales accounted for 58.
18% of the overall market, a decrease of 2.
2 units from 2019 Percentage points
.
The importance of retail pharmacies in the pharmaceutical market is increasing.
In 2020, China's retail pharmacies accounted for 26.
02% of drug sales, an increase of 1.
8 percentage points from 2019
.
Driven by hierarchical diagnosis and treatment and centralized procurement, channel sinking has become a marketing strategy for pharmaceutical companies, and the proportion of drug sales in primary medical institutions is on the rise
.
China's pharmaceutical market pattern from 2016 to 2020
Data source: Blue Book of China's Health Industry
In 2021, the National Development and Reform Commission and the Ministry of Commerce issued the "Opinions on Supporting the Construction of Hainan Free Trade Port to Relax Certain Special Measures for Market Access", proposing support for Hainan's Internet prescription drug sales, which means the opening of online prescription drugs
.
This is the country's blockbuster policy to promote the integration of the Internet and medicine following the "Internet + medical" and "Internet + medical insurance"
.
.
This is the country's blockbuster policy to promote the integration of the Internet and medicine following the "Internet + medical" and "Internet + medical insurance"
.
The policy's standardization and support of "Internet + medicine" has expanded the space and time scope of the outflow of drug prescriptions
.
In recent years, patients have gradually developed the habit of buying drugs online, and online drug retail business has been in full swing, and sales have grown rapidly at a rate of over 40%
.
In 2020, catalyzed by the new crown pneumonia epidemic, online economic vitality will be further activated, with annual online drug sales reaching 24.
3 billion yuan, a growth rate of 75.
60%
.
.
In recent years, patients have gradually developed the habit of buying drugs online, and online drug retail business has been in full swing, and sales have grown rapidly at a rate of over 40%
.
In 2020, catalyzed by the new crown pneumonia epidemic, online economic vitality will be further activated, with annual online drug sales reaching 24.
3 billion yuan, a growth rate of 75.
60%
.
2016-2020 China's online pharmacy drug sales and growth rate
Data source: Blue Book of China's Health Industry
During the "13th Five-Year Plan" period, the market structure of China's pharmaceutical industry has undergone significant changes
.
What are the underlying reasons for these changes? Which aspects of the industry have an important impact?
.
What are the underlying reasons for these changes? Which aspects of the industry have an important impact?
Recently, Hengrui's share price was cut in half and Dongyang Sunshine announced that it intends to divest its pharmaceutical business and other events that have attracted industry attention
.
Ripples frequently occur in China's pharmaceutical industry
.
.
Ripples frequently occur in China's pharmaceutical industry
.
Everything has historical reasons, either macroscopically or microscopically
.
Looking back, since the "13th Five-Year Plan", China's pharmaceutical industry has carried out drastic reforms, the industry's "metabolism" has accelerated, and the market structure has been restructured
.
Catalyzed by the impact of the new crown pneumonia epidemic, China's pharmaceutical industry has accelerated its restructuring amid opportunities and challenges
.
.
Looking back, since the "13th Five-Year Plan", China's pharmaceutical industry has carried out drastic reforms, the industry's "metabolism" has accelerated, and the market structure has been restructured
.
Catalyzed by the impact of the new crown pneumonia epidemic, China's pharmaceutical industry has accelerated its restructuring amid opportunities and challenges
.
The market is the ultimate manifestation of the development characteristics of all levels of the industry
.
From the perspective of the market, this article briefly presents and analyzes the turbulent history of China's pharmaceutical industry during the 13th Five-Year Plan period
.
.
From the perspective of the market, this article briefly presents and analyzes the turbulent history of China's pharmaceutical industry during the 13th Five-Year Plan period
.
Market differentiation: Biological medicines are gaining momentum, Chinese medicines remain stable, and chemical medicines are not in sight
After years of market expansion, the market size of China's pharmaceutical industry will exceed 1.
700 billion yuan in 2020
.
Among the three major areas, biological drugs are developing rapidly, and their scale proportions are increasing year by year, reaching 20.
84% in 2020; the proportion of traditional Chinese medicines is stable, remaining at about 25%; chemical medicines are in the transitional period, and the market share has dropped significantly, and its loss is This can be seen in the recent incidents of traditional large chemical pharmaceutical companies such as Hengrui and Dongyang Sunshine
.
The differentiated development of the three major pharmaceutical markets is closely related to the implementation of policies in each field and the entry of new products
.
700 billion yuan in 2020
.
Among the three major areas, biological drugs are developing rapidly, and their scale proportions are increasing year by year, reaching 20.
84% in 2020; the proportion of traditional Chinese medicines is stable, remaining at about 25%; chemical medicines are in the transitional period, and the market share has dropped significantly, and its loss is This can be seen in the recent incidents of traditional large chemical pharmaceutical companies such as Hengrui and Dongyang Sunshine
.
The differentiated development of the three major pharmaceutical markets is closely related to the implementation of policies in each field and the entry of new products
.
2016-2020 China's pharmaceutical industry market size and market segment proportions
Data source: Blue Book of China's Health Industry
Market differentiation is also reflected in the change of heavyweight varieties
.
From 2016 to 2020, among the Top 20 categories of drug sales in the Chinese hospital market, many products have either changed their rankings or entered or departed from the rankings
.
Chemical drugs such as atorvastatin, clopidogrel, and entecavir have gradually disappeared from the Top 20 list after undergoing centralized harvesting, while biological drugs such as bevacizumab and trastuzumab have been eye-catching
.
.
From 2016 to 2020, among the Top 20 categories of drug sales in the Chinese hospital market, many products have either changed their rankings or entered or departed from the rankings
.
Chemical drugs such as atorvastatin, clopidogrel, and entecavir have gradually disappeared from the Top 20 list after undergoing centralized harvesting, while biological drugs such as bevacizumab and trastuzumab have been eye-catching
.
Changes in the List of Top 20 Drug Sales in China's Hospital Market from 2016 to 2020
Data source: Pharmaceutical Comprehensive Database (PDB), China Pharmaceutical Industry Information Center
Increased concentration: industry structure changes under the empowerment of heavy new varieties
In recent years, the market concentration of China's pharmaceutical industry has increased rapidly
.
From 2016 to 2020, the market share of Top 20 corporate hospitals has steadily increased, reaching 26.
26% in 2016 and reaching 32.
82% in 2020
.
Top20 companies have occupied nearly one-third of the hospital market
.
.
From 2016 to 2020, the market share of Top 20 corporate hospitals has steadily increased, reaching 26.
26% in 2016 and reaching 32.
82% in 2020
.
Top20 companies have occupied nearly one-third of the hospital market
.
Changes in market share of top 20 companies in China's hospital market by drug sales from 2016 to 2020
Data source: Pharmaceutical Comprehensive Database (PDB), China Pharmaceutical Industry Information Center
Among the Top 20 companies, the number of foreign-funded companies has increased from 9 in 2016 to 11 in 2020, and the total market share of foreign-funded companies has increased from 51.
26% in 2016 to 61.
82% in 2020.
This is in line with the acceleration of foreign blockbuster innovative products to enter the domestic market.
Closely related
.
26% in 2016 to 61.
82% in 2020.
This is in line with the acceleration of foreign blockbuster innovative products to enter the domestic market.
Closely related
.
Changes in the share of Chinese domestic and foreign companies in the top 20 pharmaceutical sales in China's hospital market from 2016 to 2020
Data source: Pharmaceutical Comprehensive Database (PDB), China Pharmaceutical Industry Information Center
Under the influence of factors such as the acceleration of the review and approval of new drugs by the State Food and Drug Administration, acceptance of overseas clinical trial data, centralized procurement to promote patent cliffs, and more convenient access to medical insurance catalogs, foreign companies have accelerated the entry of new products into China
.
Taking imported chemical drugs as an example, from 2016 to 2020, the total number of clinical trial applications and marketing applications for imported chemical drugs accepted by CDE has increased year by year
.
In 2020, a total of 3 imported innovative drugs will be applied for listing in China.
Compared with 1 in 2018 and 2019, there is a significant breakthrough
.
The admission of new overseas varieties has greatly benefited the availability of medicines for Chinese patients
.
.
Taking imported chemical drugs as an example, from 2016 to 2020, the total number of clinical trial applications and marketing applications for imported chemical drugs accepted by CDE has increased year by year
.
In 2020, a total of 3 imported innovative drugs will be applied for listing in China.
Compared with 1 in 2018 and 2019, there is a significant breakthrough
.
The admission of new overseas varieties has greatly benefited the availability of medicines for Chinese patients
.
2016-2020 China imported chemical drug clinical trial application status (according to the acceptance number)
Data source: China New Drug Research and Development Monitoring Database (CPM), China Pharmaceutical Industry Information Center
2016-2020 China's import chemical drug listing application status (according to the acceptance number)
Data source: China New Drug Research and Development Monitoring Database (CPM), China Pharmaceutical Industry Information Center
Imported innovative drug listing application information
Data source: China New Drug Research and Development Monitoring Database (CPM), China Pharmaceutical Industry Information Center
Channel adjustment: multi-method incremental exploration
With the implementation of prescription outflow and centralized procurement policies, the stock of the hospital market has shrunk, and the out-of-hospital market has become a gold dig for pharmaceutical companies
.
After years of drug control fees and prescription assessments, public medical institutions are still the main drug sales market in China, but their market share is steadily decreasing.
In 2020, public medical institutions’ drug sales accounted for 58.
18% of the overall market, a decrease of 2.
2 units from 2019 Percentage points
.
The importance of retail pharmacies in the pharmaceutical market is increasing.
In 2020, China's retail pharmacies accounted for 26.
02% of drug sales, an increase of 1.
8 percentage points from 2019
.
Driven by hierarchical diagnosis and treatment and centralized procurement, channel sinking has become a marketing strategy for pharmaceutical companies, and the proportion of drug sales in primary medical institutions is on the rise
.
.
After years of drug control fees and prescription assessments, public medical institutions are still the main drug sales market in China, but their market share is steadily decreasing.
In 2020, public medical institutions’ drug sales accounted for 58.
18% of the overall market, a decrease of 2.
2 units from 2019 Percentage points
.
The importance of retail pharmacies in the pharmaceutical market is increasing.
In 2020, China's retail pharmacies accounted for 26.
02% of drug sales, an increase of 1.
8 percentage points from 2019
.
Driven by hierarchical diagnosis and treatment and centralized procurement, channel sinking has become a marketing strategy for pharmaceutical companies, and the proportion of drug sales in primary medical institutions is on the rise
.
China's pharmaceutical market pattern from 2016 to 2020
Data source: Blue Book of China's Health Industry
In 2021, the National Development and Reform Commission and the Ministry of Commerce issued the "Opinions on Supporting the Construction of Hainan Free Trade Port to Relax Certain Special Measures for Market Access", proposing support for Hainan's Internet prescription drug sales, which means the opening of online prescription drugs
.
This is the country's blockbuster policy to promote the integration of the Internet and medicine following the "Internet + medical" and "Internet + medical insurance"
.
.
This is the country's blockbuster policy to promote the integration of the Internet and medicine following the "Internet + medical" and "Internet + medical insurance"
.
The policy's standardization and support of "Internet + medicine" has expanded the space and time scope of the outflow of drug prescriptions
.
In recent years, patients have gradually developed the habit of buying drugs online, and online drug retail business has been in full swing, and sales have grown rapidly at a rate of over 40%
.
In 2020, catalyzed by the new crown pneumonia epidemic, online economic vitality will be further activated, with annual online drug sales reaching 24.
3 billion yuan, a growth rate of 75.
60%
.
.
In recent years, patients have gradually developed the habit of buying drugs online, and online drug retail business has been in full swing, and sales have grown rapidly at a rate of over 40%
.
In 2020, catalyzed by the new crown pneumonia epidemic, online economic vitality will be further activated, with annual online drug sales reaching 24.
3 billion yuan, a growth rate of 75.
60%
.
2016-2020 China's online pharmacy drug sales and growth rate
Data source: Blue Book of China's Health Industry
During the "13th Five-Year Plan" period, the market structure of China's pharmaceutical industry has undergone significant changes
.
What are the underlying reasons for these changes? Which aspects of the industry have an important impact?
.
What are the underlying reasons for these changes? Which aspects of the industry have an important impact?
Recently, Hengrui's share price was cut in half and Dongyang Sunshine announced that it intends to divest its pharmaceutical business and other events that have attracted industry attention
.
Ripples frequently occur in China's pharmaceutical industry
.
Medicine Medicine Medicine.
Ripples frequently occur in China's pharmaceutical industry
.
Everything has historical reasons, either macroscopically or microscopically
.
Looking back, since the "13th Five-Year Plan", China's pharmaceutical industry has carried out drastic reforms, the industry's "metabolism" has accelerated, and the market structure has been restructured
.
Catalyzed by the impact of the new crown pneumonia epidemic, China's pharmaceutical industry has accelerated its restructuring amid opportunities and challenges
.
.
Looking back, since the "13th Five-Year Plan", China's pharmaceutical industry has carried out drastic reforms, the industry's "metabolism" has accelerated, and the market structure has been restructured
.
Catalyzed by the impact of the new crown pneumonia epidemic, China's pharmaceutical industry has accelerated its restructuring amid opportunities and challenges
.
The market is the ultimate manifestation of the development characteristics of all levels of the industry
.
From the perspective of the market, this article briefly presents and analyzes the turbulent history of China's pharmaceutical industry during the 13th Five-Year Plan period
.
.
From the perspective of the market, this article briefly presents and analyzes the turbulent history of China's pharmaceutical industry during the 13th Five-Year Plan period
.
Market differentiation: Biological medicines are gaining momentum, Chinese medicines remain stable, and chemical medicines are not in sight
After years of market expansion, the market size of China's pharmaceutical industry will exceed 1.
700 billion yuan in 2020
.
Among the three major areas, biological drugs are developing rapidly, and their scale proportions are increasing year by year, reaching 20.
84% in 2020; the proportion of traditional Chinese medicines is stable, remaining at about 25%; chemical medicines are in the transitional period, and the market share has dropped significantly, and its loss is This can be seen in the recent incidents of traditional large chemical pharmaceutical companies such as Hengrui and Dongyang Sunshine
.
The differentiated development of the three major pharmaceutical markets is closely related to the implementation of policies in each field and the entry of new products
.
700 billion yuan in 2020
.
Among the three major areas, biological drugs are developing rapidly, and their scale proportions are increasing year by year, reaching 20.
84% in 2020; the proportion of traditional Chinese medicines is stable, remaining at about 25%; chemical medicines are in the transitional period, and the market share has dropped significantly, and its loss is This can be seen in the recent incidents of traditional large chemical pharmaceutical companies such as Hengrui and Dongyang Sunshine
.
The differentiated development of the three major pharmaceutical markets is closely related to the implementation of policies in each field and the entry of new products
.
2016-2020 China's pharmaceutical industry market size and market segment proportions
Data source: Blue Book of China's Health Industry
Market differentiation is also reflected in the change of heavyweight varieties
.
From 2016 to 2020, among the Top 20 categories of drug sales in the Chinese hospital market, many products have either changed their rankings or entered or departed from the rankings
.
Chemical drugs such as atorvastatin, clopidogrel, and entecavir have gradually disappeared from the Top 20 list after undergoing centralized harvesting, while biological drugs such as bevacizumab and trastuzumab have been eye-catching
.
.
From 2016 to 2020, among the Top 20 categories of drug sales in the Chinese hospital market, many products have either changed their rankings or entered or departed from the rankings
.
Chemical drugs such as atorvastatin, clopidogrel, and entecavir have gradually disappeared from the Top 20 list after undergoing centralized harvesting, while biological drugs such as bevacizumab and trastuzumab have been eye-catching
.
Changes in the List of Top 20 Drug Sales in China's Hospital Market from 2016 to 2020
Data source: Pharmaceutical Comprehensive Database (PDB), China Pharmaceutical Industry Information Center
Increased concentration: industry structure changes under the empowerment of heavy new varieties
Increased concentration: industry structure changes under the empowerment of heavy new varieties In recent years, the market concentration of China's pharmaceutical industry has increased rapidly
.
From 2016 to 2020, the market share of Top 20 corporate hospitals has steadily increased, reaching 26.
26% in 2016 and reaching 32.
82% in 2020
.
Top20 companies have occupied nearly one-third of the hospital market
.
Enterprise Hospital business enterprises Hospital Hospital.
From 2016 to 2020, the market share of Top 20 corporate hospitals has steadily increased, reaching 26.
26% in 2016 and reaching 32.
82% in 2020
.
Top20 companies have occupied nearly one-third of the hospital market
.
Changes in market share of top 20 companies in China's hospital market by drug sales from 2016 to 2020
Data source: Pharmaceutical Comprehensive Database (PDB), China Pharmaceutical Industry Information Center
Among the Top 20 companies, the number of foreign-funded companies has increased from 9 in 2016 to 11 in 2020, and the total market share of foreign-funded companies has increased from 51.
26% in 2016 to 61.
82% in 2020.
This is in line with the acceleration of foreign blockbuster innovative products to enter the domestic market.
Closely related
.
26% in 2016 to 61.
82% in 2020.
This is in line with the acceleration of foreign blockbuster innovative products to enter the domestic market.
Closely related
.
Changes in the share of Chinese domestic and foreign companies in the top 20 pharmaceutical sales in China's hospital market from 2016 to 2020
Data source: Pharmaceutical Comprehensive Database (PDB), China Pharmaceutical Industry Information Center
Under the influence of factors such as the acceleration of the review and approval of new drugs by the State Food and Drug Administration, acceptance of overseas clinical trial data, centralized procurement to promote patent cliffs, and more convenient access to medical insurance catalogs, foreign companies have accelerated the entry of new products into China
.
Taking imported chemical drugs as an example, from 2016 to 2020, the total number of clinical trial applications and marketing applications for imported chemical drugs accepted by CDE has increased year by year
.
In 2020, a total of 3 imported innovative drugs will be applied for listing in China.
Compared with 1 in 2018 and 2019, there is a significant breakthrough
.
The admission of new overseas varieties has greatly benefited the availability of medicines for Chinese patients
.
.
Taking imported chemical drugs as an example, from 2016 to 2020, the total number of clinical trial applications and marketing applications for imported chemical drugs accepted by CDE has increased year by year
.
In 2020, a total of 3 imported innovative drugs will be applied for listing in China.
Compared with 1 in 2018 and 2019, there is a significant breakthrough
.
The admission of new overseas varieties has greatly benefited the availability of medicines for Chinese patients
.
2016-2020 China imported chemical drug clinical trial application status (according to the acceptance number)
Data source: China New Drug Research and Development Monitoring Database (CPM), China Pharmaceutical Industry Information Center
2016-2020 China's import chemical drug listing application status (according to the acceptance number)
Data source: China New Drug Research and Development Monitoring Database (CPM), China Pharmaceutical Industry Information Center
Imported innovative drug listing application information
Imported innovative drug listing application information Data source: China New Drug Research and Development Monitoring Database (CPM), China Pharmaceutical Industry Information Center
Channel adjustment: multi-method incremental exploration
With the implementation of prescription outflow and centralized procurement policies, the stock of the hospital market has shrunk, and the out-of-hospital market has become a gold dig for pharmaceutical companies
.
After years of drug control fees and prescription assessments, public medical institutions are still the main drug sales market in China, but their market share is steadily decreasing.
In 2020, public medical institutions’ drug sales accounted for 58.
18% of the overall market, a decrease of 2.
2 units from 2019 Percentage points
.
The importance of retail pharmacies in the pharmaceutical market is increasing.
In 2020, China's retail pharmacies accounted for 26.
02% of drug sales, an increase of 1.
8 percentage points from 2019
.
Driven by hierarchical diagnosis and treatment and centralized procurement, channel sinking has become a marketing strategy for pharmaceutical companies, and the proportion of drug sales in primary medical institutions is on the rise
.
Pharmacy pharmacy pharmacy.
After years of drug control fees and prescription assessments, public medical institutions are still the main drug sales market in China, but their market share is steadily decreasing.
In 2020, public medical institutions’ drug sales accounted for 58.
18% of the overall market, a decrease of 2.
2 units from 2019 Percentage points
.
The importance of retail pharmacies in the pharmaceutical market is increasing.
In 2020, China's retail pharmacies accounted for 26.
02% of drug sales, an increase of 1.
8 percentage points from 2019
.
Driven by hierarchical diagnosis and treatment and centralized procurement, channel sinking has become a marketing strategy for pharmaceutical companies, and the proportion of drug sales in primary medical institutions is on the rise
.
China's pharmaceutical market pattern from 2016 to 2020
Data source: Blue Book of China's Health Industry
In 2021, the National Development and Reform Commission and the Ministry of Commerce issued the "Opinions on Supporting the Construction of Hainan Free Trade Port to Relax Certain Special Measures for Market Access", proposing support for Hainan's Internet prescription drug sales, which means the opening of online prescription drugs
.
This is the country's blockbuster policy to promote the integration of the Internet and medicine following the "Internet + medical" and "Internet + medical insurance"
.
.
This is the country's blockbuster policy to promote the integration of the Internet and medicine following the "Internet + medical" and "Internet + medical insurance"
.
The policy's standardization and support of "Internet + medicine" has expanded the space and time scope of the outflow of drug prescriptions
.
In recent years, patients have gradually developed the habit of buying drugs online, and online drug retail business has been in full swing, and sales have grown rapidly at a rate of over 40%
.
In 2020, catalyzed by the new crown pneumonia epidemic, online economic vitality will be further activated, with annual online drug sales reaching 24.
3 billion yuan, a growth rate of 75.
60%
.
Medicine, medicine, medicine.
In recent years, patients have gradually developed the habit of buying drugs online, and online drug retail business has been in full swing, and sales have grown rapidly at a rate of over 40%
.
In 2020, catalyzed by the new crown pneumonia epidemic, online economic vitality will be further activated, with annual online drug sales reaching 24.
3 billion yuan, a growth rate of 75.
60%
.
2016-2020 China's online pharmacy drug sales and growth rate
Data source: Blue Book of China's Health Industry
